Latest news with #Fujirebio
New York Times
21-05-2025
- Health
- New York Times
A Blood Test for Alzheimer's: What to Know
A blood test that can help diagnose Alzheimer's disease has received clearance from the Food and Drug Administration. This is a step toward a goal of scientists and doctors to one day be able to diagnose a confounding illness with the prick of a finger. But there is still a long way to go. Here is what to know: What is the test, and how should it be used? The test, manufactured by Fujirebio Diagnostics, is intended to be used only by specialists in Alzheimer's, the F.D.A. said. Its mouthful of a name — Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio — describes what the test measures: levels of two proteins, amyloid and tau, that are hallmarks of Alzheimer's disease. In people who develop Alzheimer's, amyloid begins to accumulate and form plaques in the brain more than 20 years before any symptoms of cognitive impairment. Tau accumulates later, forming tangles in the brain, and is much more closely correlated with cognitive decline. Can people who don't have memory problems take the blood test? No. The F.D.A., and Alzheimer's experts, emphasized that the blood test should be given only to people who are already experiencing cognitive decline and are ages 55 and older. Moreover, it should not be used on its own to diagnose or to rule out Alzheimer's. 'Other clinical evaluations or additional tests should be used for determining treatment options,' the F.D.A. said in a statement, adding that 'the results must be interpreted in conjunction with other patient clinical information.' The current gold standard for diagnosing Alzheimer's still involves either imaging using PET scans, which are expensive, or spinal taps, which are invasive. The blood test can help flag the presence of the Alzheimer's-related proteins, and doctors might then order confirmatory testing with one of the other methods. Patients interested in getting the blood test should be referred to dementia clinics or similar settings. But before getting it, experts said, a patient should undergo cognitive tests that assess memory and thinking and possibly CT scans that look for alternative causes like strokes or brain tumors. How accurate is the test? The test measures two forms of the proteins — pTau217 and beta-amyloid 1-42 — in plasma, a component of blood, and then compares the ratio of those two proteins with the presence or absence of amyloid plaques in a patient's brain, the F.D.A. said. The agency said that it had evaluated a study of 499 plasma samples from patients who were cognitively impaired and compared the results of the blood test with assessments of the patients by PET scan or spinal tap. The study found that the blood test was nearly 92 percent as accurate as a PET scan or a spinal tap in flagging people with Alzheimer's pathology. It was over 97 percent as accurate as those measures in identifying people who did not have Alzheimer's pathology. The blood test didn't always yield a positive or negative result. It was indeterminate in less than 20 percent of the cases, the F.D.A. said. The agency noted that because the test wasn't 100 percent accurate, there was a risk of false positive or false negative results. 'False positive results, in conjunction with other clinical information, could lead to an inappropriate diagnosis of, and unnecessary treatment for, Alzheimer's disease,' the F.D.A. said. 'This could lead to psychological distress, delay in receiving a correct diagnosis as well as expense and the risk for side effects from unnecessary treatment. False negative results could result in additional unnecessary diagnostic tests and potential delay in effective treatment.' What implications could this test have for people with Alzheimer's? This is not the first blood test to be developed for Alzheimer's, but it is the first to be cleared for marketing. Specialists have been using blood tests like this for several years, often to screen participants for clinical trials and to help pinpoint if a patient's dementia is caused by Alzheimer's. But the F.D.A. clearance of the Lumipulse test is likely to make more doctors, patients and families aware of the option and such blood tests more widely available. The test could allow more patients to receive accurate diagnoses for the causes of their cognitive impairment. Alzheimer's disease is the most common dementia, but there are other types, including vascular dementia and Lewy body dementia, that have different underlying pathologies. Differentiating between types of dementia has become increasingly important, partly because in the last two years two drugs that attack amyloid, Leqembi and Kisunla, have been approved for patients with cognitive impairment who are in the early stages of Alzheimer's disease. The drugs appear to modestly slow cognitive decline in mildly impaired patients, but also carry risks of swelling and bleeding in the brain. Drug companies have been encouraging efforts to diagnose more people early to identify patients eligible for these drugs. And experts say it is just as important to identify patients who are not candidates for the drugs so they don't receive inappropriate treatment.
South China Morning Post
21-05-2025
- Health
- South China Morning Post
First blood test to diagnose Alzheimer's disease to be available in US starting late June
The first blood test to help diagnose Alzheimer's disease will be available from late June in the US following regulatory clearance for its use last week, according to the Japanese company behind the innovation. The test will initially be available at about 50 American research institutes and hospitals that specialise in Alzheimer's disease, Goki Ishikawa, head of Fujirebio Holdings, a unit of Japan's H.U. Group Holdings, said in an interview Tuesday. It's partnering with bigger rivals like Beckman Coulter to help develop and manufacture their products, he said. The Food and Drug Administration cleared the blood test to help diagnose Alzheimer's disease last week, potentially making it easier to find and treat patients with the memory-robbing disease that affects nearly 7 million Americans. The test was cleared for use in people at least 55 years old and who exhibit signs of the disease. It is designed to detect amyloid, a protein that can build up in the brain and is a hallmark of Alzheimer's, the most common form of dementia in the elderly. The process, which takes roughly 30 minutes from drawing the blood to diagnosis, will be available to patients at a fraction of the cost of a PET scan. The method is viewed as a critical step in making new types of Alzheimer's treatments widely accessible. Until now, patients typically have to get a specialised PET scan to detect amyloid in their brains or undergo cerebrospinal fluid tests, both of which are more expensive and invasive. The lack of quick and easy tests has until now slowed the roll-out of new Alzheimer's drugs like Eisai and Biogen's Leqembi and Eli Lilly's Kisunla.
Yahoo
21-05-2025
- Health
- Yahoo
Global Alzheimer's Platform Foundation Applauds FDA Authorization of the First Blood-Based Diagnostic Test for Assessing Alzheimer's Disease
WASHINGTON, May 20, 2025 (GLOBE NEWSWIRE) -- The Global Alzheimer's Platform Foundation® (GAP) applauds the FDA's clearance of the first blood test to diagnose Alzheimer's disease. Fujirebio's Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio invitro diagnostic (IVD) represents the first blood-based test available to physicians and their patients for early detection of amyloid plaques associated with Alzheimer's—a critical element in accurately diagnosing Alzheimer's disease (AD). This new test presents a faster, less invasive and much more accessible method for diagnosis, in contrast with tests based on a PET scan or collection of cerebral spinal fluid (CSF). GAP is proud that its AD biomarker study, Bio-Hermes-001, played a principal role in the dataset used to support Fujirebio's FDA application for clearance of the first groundbreaking blood based IVD available for the diagnosis of Alzheimer's Disease (AD). Bio-Hermes-001 was designed to provide head-to-head comparisons of data available on leading Alzheimer's blood tests and PET tests from 1,000 highly characterized and representative study volunteers demonstrating signs and symptoms associated with Alzheimer's disease. John Dwyer, President of the Global Alzheimer's Platform Foundation stated, 'We commend the FDA's clearance of Fujirebio's Lumipulse submission, as this IVD is poised to fundamentally change the Alzheimer's diagnostic process and significantly improve the ability of physicians to accurately access and treat AD and empower people to take action to address their condition. GAP is extremely proud that its Bio-Hermes-001 biomarker study materially contributed to this landmark IVD. We intentionally designed that unique study to drive forward new technologies and treatment processes for Alzheimer's and related dementias. We want to thank the thousand volunteers who participated in Bio-Hermes 1; the numerous clinical trial sites that tirelessly worked with us on the study as well as the dozens of technology, pharmaceutical, and philanthropy partners that collaborated with us to support Bio-Hermes. GAP celebrates this remarkable clearance, which has the potential to transform the future of AD diagnostics and treatments.' About the Global Alzheimer's Platform Foundation (GAP)The nonprofit Global Alzheimer's Platform Foundation was founded to speed the delivery of Alzheimer's treatments with a commitment to promoting diversity in clinical research, as well as lowering the cost and improving the efficacy of ADRD clinical trials to ensure that no one is left behind. As part of its mission, GAP supports more than 100 clinical research sites worldwide through study start-up and recruitment activities, promoting diversity in research studies, and giving attention to the citizen scientists who make research possible. Contact: media@
Yahoo
20-05-2025
- Health
- Yahoo
Global Alzheimer's Platform Foundation Applauds FDA Authorization of the First Blood-Based Diagnostic Test for Assessing Alzheimer's Disease
WASHINGTON, May 20, 2025 (GLOBE NEWSWIRE) -- The Global Alzheimer's Platform Foundation® (GAP) applauds the FDA's clearance of the first blood test to diagnose Alzheimer's disease. Fujirebio's Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio invitro diagnostic (IVD) represents the first blood-based test available to physicians and their patients for early detection of amyloid plaques associated with Alzheimer's—a critical element in accurately diagnosing Alzheimer's disease (AD). This new test presents a faster, less invasive and much more accessible method for diagnosis, in contrast with tests based on a PET scan or collection of cerebral spinal fluid (CSF). GAP is proud that its AD biomarker study, Bio-Hermes-001, played a principal role in the dataset used to support Fujirebio's FDA application for clearance of the first groundbreaking blood based IVD available for the diagnosis of Alzheimer's Disease (AD). Bio-Hermes-001 was designed to provide head-to-head comparisons of data available on leading Alzheimer's blood tests and PET tests from 1,000 highly characterized and representative study volunteers demonstrating signs and symptoms associated with Alzheimer's disease. John Dwyer, President of the Global Alzheimer's Platform Foundation stated, 'We commend the FDA's clearance of Fujirebio's Lumipulse submission, as this IVD is poised to fundamentally change the Alzheimer's diagnostic process and significantly improve the ability of physicians to accurately access and treat AD and empower people to take action to address their condition. GAP is extremely proud that its Bio-Hermes-001 biomarker study materially contributed to this landmark IVD. We intentionally designed that unique study to drive forward new technologies and treatment processes for Alzheimer's and related dementias. We want to thank the thousand volunteers who participated in Bio-Hermes 1; the numerous clinical trial sites that tirelessly worked with us on the study as well as the dozens of technology, pharmaceutical, and philanthropy partners that collaborated with us to support Bio-Hermes. GAP celebrates this remarkable clearance, which has the potential to transform the future of AD diagnostics and treatments.' About the Global Alzheimer's Platform Foundation (GAP)The nonprofit Global Alzheimer's Platform Foundation was founded to speed the delivery of Alzheimer's treatments with a commitment to promoting diversity in clinical research, as well as lowering the cost and improving the efficacy of ADRD clinical trials to ensure that no one is left behind. As part of its mission, GAP supports more than 100 clinical research sites worldwide through study start-up and recruitment activities, promoting diversity in research studies, and giving attention to the citizen scientists who make research possible. Contact: media@
Yahoo
20-05-2025
- Health
- Yahoo
Global Alzheimer's Platform Foundation Applauds FDA Authorization of the First Blood-Based Diagnostic Test for Assessing Alzheimer's Disease
WASHINGTON, May 20, 2025 (GLOBE NEWSWIRE) -- The Global Alzheimer's Platform Foundation® (GAP) applauds the FDA's clearance of the first blood test to diagnose Alzheimer's disease. Fujirebio's Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio invitro diagnostic (IVD) represents the first blood-based test available to physicians and their patients for early detection of amyloid plaques associated with Alzheimer's—a critical element in accurately diagnosing Alzheimer's disease (AD). This new test presents a faster, less invasive and much more accessible method for diagnosis, in contrast with tests based on a PET scan or collection of cerebral spinal fluid (CSF). GAP is proud that its AD biomarker study, Bio-Hermes-001, played a principal role in the dataset used to support Fujirebio's FDA application for clearance of the first groundbreaking blood based IVD available for the diagnosis of Alzheimer's Disease (AD). Bio-Hermes-001 was designed to provide head-to-head comparisons of data available on leading Alzheimer's blood tests and PET tests from 1,000 highly characterized and representative study volunteers demonstrating signs and symptoms associated with Alzheimer's disease. John Dwyer, President of the Global Alzheimer's Platform Foundation stated, 'We commend the FDA's clearance of Fujirebio's Lumipulse submission, as this IVD is poised to fundamentally change the Alzheimer's diagnostic process and significantly improve the ability of physicians to accurately access and treat AD and empower people to take action to address their condition. GAP is extremely proud that its Bio-Hermes-001 biomarker study materially contributed to this landmark IVD. We intentionally designed that unique study to drive forward new technologies and treatment processes for Alzheimer's and related dementias. We want to thank the thousand volunteers who participated in Bio-Hermes 1; the numerous clinical trial sites that tirelessly worked with us on the study as well as the dozens of technology, pharmaceutical, and philanthropy partners that collaborated with us to support Bio-Hermes. GAP celebrates this remarkable clearance, which has the potential to transform the future of AD diagnostics and treatments.' About the Global Alzheimer's Platform Foundation (GAP)The nonprofit Global Alzheimer's Platform Foundation was founded to speed the delivery of Alzheimer's treatments with a commitment to promoting diversity in clinical research, as well as lowering the cost and improving the efficacy of ADRD clinical trials to ensure that no one is left behind. As part of its mission, GAP supports more than 100 clinical research sites worldwide through study start-up and recruitment activities, promoting diversity in research studies, and giving attention to the citizen scientists who make research possible. Contact: media@
